IRIS
MORABITO, FORTUNATO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 395
EU - Europa 314
AS - Asia 236
AF - Africa 5
Totale 950
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 393
IT - Italia 234
CN - Cina 124
SG - Singapore 105
DE - Germania 27
FI - Finlandia 25
AT - Austria 10
NL - Olanda 10
CZ - Repubblica Ceca 2
ET - Etiopia 2
FR - Francia 2
JP - Giappone 2
KR - Corea 2
PA - Panama 2
SC - Seychelles 2
DK - Danimarca 1
ES - Italia 1
GB - Regno Unito 1
LT - Lituania 1
MO - Macao, regione amministrativa speciale della Cina 1
PH - Filippine 1
PK - Pakistan 1
SN - Senegal 1
Totale 950
Salva come PNG Salva come JPEG
Città #
Florence 154
Boardman 138
Singapore 87
Ashburn 63
Shanghai 41
Sesto Fiorentino 23
Noto 22
Washington 19
Helsinki 17
Munich 14
Los Angeles 11
Ogden 11
Guangzhou 10
Wuhan 9
Lappeenranta 8
Vienna 8
Naaldwijk 7
Beijing 5
Milan 5
New York 4
Amsterdam 3
Nuremberg 3
Palmi 3
Addis Ababa 2
Bari 2
Gualdo Tadino 2
Jinhua 2
Naples 2
Rome 2
Seoul 2
Shenzhen 2
Tokyo 2
Turin 2
West Jordan 2
Wuxi 2
Bologna 1
Brooklyn 1
Cascina 1
Catania 1
Chicago 1
Cirò Marina 1
Cologne 1
Dakar 1
Dalian 1
Frankfurt am Main 1
Jiaxing 1
Lianyun 1
Macao 1
Madrid 1
Manila 1
Modigliana 1
Nanjing 1
Newark 1
Ningbo 1
Qingdao 1
Rende 1
San Francisco 1
Santa Barbara 1
Santa Clara 1
Seattle 1
Shijiazhuang 1
Taizhou 1
Tiantai Chengguanzhen 1
Udine 1
Weifang 1
Yiwu 1
Zhongshan 1
Zibo 1
Totale 722
Salva come PNG Salva come JPEG
Nome #
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 35
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 33
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 33
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 32
Elotuzumab in multiple myeloma 32
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 31
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 30
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 30
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 29
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 29
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 28
Teclistamab-cqyv in multiple myeloma 27
Belantamab mafodotin in multiple myeloma 27
Iron chelation therapy 26
Myelodysplastic syndromes with ring sideroblasts 25
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 25
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 25
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 24
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 24
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 24
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 23
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 22
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 22
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 22
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 21
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 19
Acalabrutinib in chronic lymphocytic leukemia 19
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 16
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 16
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 16
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 16
Ivosidenib in acute myeloid leukemia 15
Glasdegib for the treatment of acute myeloid leukemia 14
Isatuximab in multiple myeloma 14
Momelotinib in myelofibrosis 14
Zanubrutinib for the treatment of chronic lymphocytic leukemia 14
Selinexor in multiple myeloma 12
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 12
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 12
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 11
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 11
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 10
Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period 10
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia 9
Venetoclax in acute myeloid leukemia 9
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 8
Mosunetuzumab for the treatment of follicular lymphoma 8
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 7
Tagraxofusp in myeloid malignancies 7
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 6
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 6
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 6
The role of corticosteroids in the current treatment paradigm for myelofibrosis 5
Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights 4
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 2
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 2
Totale 1.009
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.421
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.421
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202369 0 0 0 0 0 0 30 4 4 4 21 6
2023/2024599 9 14 121 91 53 90 29 21 20 10 21 120
2024/2025341 56 112 33 72 68 0 0 0 0 0 0 0
Totale 1.009